DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
NCT04696029
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
118
Enrollment
OTHER
Sponsor class
Conditions
Medulloblastoma
Interventions
DRUG:
Difluoromethylornithine
Sponsor
Giselle Sholler